ABBV Stock Recent News
ABBV LATEST HEADLINES
There's really no such thing as a “no brainer” stock pick. I'd say that some opportunities are more compelling than others.
What's better than a great dividend? A great dividend that's growing.
Are dividend stocks only for investors nearing or in retirement? Not at all.
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull and bear case to help you assess the fit. Comcast benefits from diversified cash flow through broadband, content creation, and international operations. The business remains cyclical—recessions hit industrial demand, and European expansion poses integration risks. Brand power and wide distribution provide resilience. PepsiCo is expanding its healthier product lines and boosting e-commerce. The shift toward healthier foods poses a threat to legacy products.
Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right types of dividend stocks.
Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.
AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.
The Investment Committee give you their top stocks to watch for the second half.